Guardant Health
Liquid biopsy leader: Guardant360 for genotyping, Reveal for MRD, Shield for screening.
Guardant360 CDx (companion for elacestrant, others), Guardant Reveal (tumour-naive MRD), Shield (FDA-approved CRC screening, MCD extension).
Pages like this
not linked directly; found by shared links- CompanyNatera
Shares An annual blinded shoot-out for liquid biopsy tests, Certified reference samples to benchmark every tumour-DNA blood test, Kill combination arms early using circulating tumour DNA, before waiting for scans, Reference materials and open proficiency testing for residual disease tests.
- CompanyFoundation Medicine (Roche)
Shares One open atlas of how tumours escape every drug, Drop mandatory fresh biopsies where blood or archival tissue would do, Label every targetable mutation as truncal or branch on the report, Every tumour sequencing report lists open, nearby, matched trials pulled live.
- CompanyFreenome
Shares Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy, Shield, Multi-cancer early detection (MCED), Most lethal cancers are found late.
- TermVariant allele frequency (VAF)
Shares Label every targetable mutation as truncal or branch on the report, An annual blinded shoot-out for liquid biopsy tests, Certified reference samples to benchmark every tumour-DNA blood test, Reference materials and open proficiency testing for residual disease tests.
- CompanyForesight Diagnostics
Shares Reference materials and open proficiency testing for residual disease tests, Continuous and near-continuous ctDNA monitoring, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- IdeaBank yearly blood from cancer survivors so future tests can be validated
Shares Multi-cancer early detection (MCED), Dormant cells and minimal residual disease, Data silos, Most lethal cancers are found late.
- IdeaMandatory interval-cancer audit for every blood-based screening test
Shares Shield, Multi-cancer early detection (MCED), Weak real-world evidence and registries, Most lethal cancers are found late.
- CompanyTempus AI
Shares Label every targetable mutation as truncal or branch on the report, Every tumour sequencing report lists open, nearby, matched trials pulled live, Every tumour genomic report machine-readable and deposited nationally, Weak real-world evidence and registries.